CENTOGENE News & Events Header Image Broschure


Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

ROSTOCK/BERLIN, Deutschland und CAMBRIDGE, MA, USA 21. November 2019 (GLOBE NEWSWIRE) - CENTOGENE (Nasdaq: CNTG), ein auf seltene Erkrankungen…

CAMBRIDGE, Mass. and ROSTOCK and BERLIN, Germany, November 21, 2019 (GLOBE NEWSWIRE) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on…

Focus on Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Accelerating new rare disease therapies through collaboration agreement

Global award honors entrepreneurship, innovation, and personal commitment

Supporting rare disease diagnosis, education, and clinical research

Driving Accelerated Diagnosis and Treatment Development

Driving personalized, immune-based therapy to target patients’ own immune responses

CENTOGENE biomarker measures lyso-Gb1 levels in children

Variant Prioritization Tool Driven by World’s Largest Curated Mutation Database

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us


Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.